OpenAI buys Orchestra Bio for AI-powered biopharma R&D

openai is acquiring orchestra bio to integrate ai-powered operations into life sciences research and development. this move aims to help biopharma teams accelerate drug development processes and advance new treatments. by leveraging ai, openai seeks to enhance the efficiency of r&d in the life sciences sector. the acquisition is expected to impact the biopharma industry. openai's strategy involves applying ai to improve drug development.